Not yet another negative trial-ReACTing on recent glioblastoma trials
The present ReACT trial provides data from a small randomized controlled vaccination trial that in addition to other recent immunotherapy trials in glioblastoma allows sketching a rational, advanced trial design for the development of (immune) therapies in glioblastoma elaborating on but not restric...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
April 2020
|
| In: |
Clinical cancer research
Year: 2020, Volume: 26, Issue: 7, Pages: 1535-1537 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-19-4032 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-19-4032 Verlag, lizenzpflichtig, Volltext: https://clincancerres.aacrjournals.org/content/26/7/1535 
|
| Author Notes: | Wolfgang Wick and Robin J. Wagener |
| Summary: | The present ReACT trial provides data from a small randomized controlled vaccination trial that in addition to other recent immunotherapy trials in glioblastoma allows sketching a rational, advanced trial design for the development of (immune) therapies in glioblastoma elaborating on but not restricting to biological monitoring and endpoints.See related article by Reardon et al., p. 1586 |
|---|---|
| Item Description: | Gesehen am 20.04.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-19-4032 |